Barón-Esquivias Gonzalo, Roldán Rabadán Inmaculada, García Quintana Antonio, Cerezo Manchado Juan José, Antorrena Miranda Isabel, Gómez-Barrado José Javier, Pérez Paredes Matías, Santas Enrique, Pindado Rodríguez Javier, Muñoz-Robles Jorge Andrés, Oliver-Miñarro Desamparados, Santamaría Amparo
Cardiology Service, Hospital Universitario Virgen del Rocío, Sevilla, Spain.
Cardiology Service, Hospital Universitario La Paz, Madrid, Spain.
Future Cardiol. 2020 Sep;16(5):469-480. doi: 10.2217/fca-2020-0024. Epub 2020 Mar 31.
To ascertain the clinical profile and management of edoxaban in clinical practice. Prospective, noninterventional postauthorization study of nonselected patients with atrial fibrillation treated with edoxaban from 12 European countries. Patients' baseline characteristics are presented. A total of 13,638 patients (73.6 ± 9.5 years; 76.6/23.4% edoxaban 60/30 mg; CHADS-VASc 3.1; 838 [6.1%] from Spain) were included. In Spain, the percentage of very elderly and fragile patients was greater and the risk of thromboembolism (CHADS-VASc ≥2, 98.0 vs 87.3%; p < 0.001) and bleeding (HAS-BLED, 3.2 vs 2.7; p < 0.001) was greater in patients treated with edoxaban 30 mg. The proportion of patients taking edoxaban 30 mg was similar than in ENGAGE AF-TIMI 48. In Spain, patients treated with edoxaban were older and fragile.
为确定依度沙班在临床实践中的临床特征及管理情况。对来自12个欧洲国家接受依度沙班治疗的非选择性房颤患者进行前瞻性、非干预性上市后研究。展示了患者的基线特征。共纳入13638例患者（73.6±9.5岁；76.6/23.4%接受依度沙班60/30 mg治疗；CHADS-VASc评分为3.1；838例[6.1%]来自西班牙）。在西班牙，非常年老和体弱的患者比例更高，接受30 mg依度沙班治疗的患者发生血栓栓塞（CHADS-VASc≥2，98.0%对87.3%；p<0.001）和出血（HAS-BLED评分，3.2对2.7；p<0.001）的风险更高。服用30 mg依度沙班的患者比例与ENGAGE AF-TIMI 48研究中的相似。在西班牙，接受依度沙班治疗的患者年龄更大且体弱。
